Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Below Two Hundred Day Moving Average – What’s Next?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $12.57 and traded as low as $12.57. Enanta Pharmaceuticals shares last traded at $12.65, with a volume of 114,136 shares traded.

Analyst Upgrades and Downgrades

ENTA has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Wednesday, January 21st. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Enanta Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $20.33.

Enanta Pharmaceuticals Stock Performance

The stock has a market capitalization of $367.10 million, a price-to-earnings ratio of -3.95 and a beta of 0.95. The firm’s fifty day simple moving average is $13.50 and its 200 day simple moving average is $12.57.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, February 9th. The biotechnology company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.12. Enanta Pharmaceuticals had a negative net margin of 106.80% and a negative return on equity of 78.58%. The company had revenue of $18.62 million during the quarter, compared to analysts’ expectations of $16.14 million. Analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current year.

Institutional Trading of Enanta Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. Deutsche Bank AG boosted its position in Enanta Pharmaceuticals by 4.6% during the fourth quarter. Deutsche Bank AG now owns 24,107 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 1,055 shares during the period. Public Employees Retirement System of Ohio raised its position in shares of Enanta Pharmaceuticals by 8.3% in the third quarter. Public Employees Retirement System of Ohio now owns 14,412 shares of the biotechnology company’s stock valued at $173,000 after purchasing an additional 1,100 shares during the period. Ameriprise Financial Inc. lifted its stake in shares of Enanta Pharmaceuticals by 8.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 18,007 shares of the biotechnology company’s stock worth $216,000 after buying an additional 1,383 shares during the last quarter. AlphaQuest LLC lifted its stake in shares of Enanta Pharmaceuticals by 18.1% during the 3rd quarter. AlphaQuest LLC now owns 10,198 shares of the biotechnology company’s stock worth $122,000 after buying an additional 1,562 shares during the last quarter. Finally, Sio Capital Management LLC boosted its holdings in shares of Enanta Pharmaceuticals by 1.0% during the 2nd quarter. Sio Capital Management LLC now owns 178,774 shares of the biotechnology company’s stock worth $1,352,000 after buying an additional 1,770 shares during the period. Institutional investors and hedge funds own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.